The content on this site is intended for healthcare professionals only
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Neoadjuvant ipilimumab added to nivolumab improves outcomes in resectable advanced melanoma
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
No benefit for adjuvant durvalumab in completely resected NSCLC
PFS increase but no OS increase for niraparib in advanced ovarian cancer
ESMO 2024: Highlights and analysis
Watchful waiting vs intravesical BCG in high grade pT1 bladder cancer
Durvalumab and oleclumab boost for SBRT plus chemo in ER+/HER2- breast cancer
Faecal microbiota transplantation increases activity of immunotherapy in mRCC
Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma
Novel antibody drug conjugate TORL-1-23 shows preliminary antitumour activity in heavily-pretreated ovarian, endometrial, and testicular cancers
Total neoadjuvant treatment without surgery for locally advanced rectal cancer
Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy
Radiation therapy for breast cancer can be safely shortened by changing technique
ESMO 2024: Latest in bladder cancer - expert review
Cancer mutation prediction using artificial intelligence
No OS improvement over chemo from capivasertib plus paclitaxel in advanced TNBC
Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours
Mirvetuximab soravtansine shows promise in FRα-positive, platinum-sensitive ovarian cancer
ESMO 2024: Latest in EGFR mutated NSCLC
Improved structure preservation with neo-adjuvant platinum-based chemo in patients with resectable NPNSCC
Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous cell carcinoma of the anal canal
TNBC: Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS compared to neoadjuvant chemo alone
Understanding the use of PARPi combinations to treat patients with mCRPC
Enzalutamide treatment boosted by Radium-223 in mCRPC
TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC
Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC
Nivolumab plus ipilimumab improves efficacy versus standard of care in non-clear-cell renal cell carcinomas
Breastfeeding after breast cancer is safe
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Repeat immune checkpoint inhibitor therapy not recommended for aRCC
